Boy with glasses and bricks

I AM
BUILDING BETTER
FRIENDSHIPS

I AM MORE THAN MY ADHD

Xenidate XL is a treatment for Attention Deficit Hyperactivity Disorder (ADHD) which contains a medicine called methylphenidate hydrochloride. It’s the same medicine as Concerta XL® with the same benefits, just with a different brand name.

Your switch

Xenidate XL provides the same pattern of daily calm as Concerta XL

FIND OUT MORE

About Xenidate XL

Switching to Xenidate XL is simple with the right support

WHAT IS XENIDATE XL?

More than my ADHD

Help your child become more than their ADHD

LIVE LIFE WELL WITH ADHD

Your support

Feel supported through the process of switching to Xenidate XL

GET SUPPORT MATERIALS
Viatris

If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme.
It is easiest and quickest to report side effects and device failures online via the Yellow Card website:  https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at pv.uk@viatris.com.

| Contact us | Privacy policy | T&Cs | Data Protection | Sitemap

Copyright © 2022 Viatris Inc. All rights reserved.
The content on this site is intended for use with UK members of the public only.
Concerta XL® is a registered trademark of Janssen-Cilag Ltd
This website is owned and managed by Viatris

Please note, while efforts have been made to choose reputable sources, Viatris cannot take responsibility on these pages maintained by external providers.
We recommend that you read the full patient information leaftlet leaflet carefully before using Xenidate XL

Xenidate XL Indication: As part of a comprehensive treatment programme for Attention Deficit/Hyperactivity Disorder (ADHD) in children aged 6 years and over and adolescents when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders

MET-2021-0013
Date of Preparation: June 2022.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)